Please login to the form below

Not currently logged in
Email:
Password:

Michael Zaiac moves from GSK to Celgene

He takes up the role of VP, medical affairs, haematology-oncology EMEA

Celgene Michael ZaiacCelgene has appointed Michael Zaiac as vice president, medical affairs for its EMEA haematology-oncology business.

Zaiac joins the company's Switzerland-based international business from GlaxoSmithKline, where he was most recently franchise medical head for its immuno-inflammation and infectious diseases operations.

Prior to joining the pharmaceutical industry Zaiac served for several years as senior house officer in the UK in general, orthopaedic and cardiothoracic surgery, as well as working in Germany in general and vascular surgery and surgical oncology.

Marie-France Tschudin, corporate vice president of haematology-oncology at Celgene International, said “I am really pleased to have Michael on board to head up our haematology-oncology medical affairs team.

“This is a really exciting time for Celgene in EMEA, with three European approvals already in 2015, two of which are in haematology-oncology. His expertise in this area will give us the strong support we need at this fast-moving time.”

13th May 2015

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics